Abivax SA
PAR:ABVX
Abivax SA
Total Current Liabilities
Abivax SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Total Current Liabilities
€112m
|
CAGR 3-Years
49%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Current Liabilities
€150.5m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
12%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Current Liabilities
€41.6m
|
CAGR 3-Years
6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
14%
|
|
|
Inventiva SA
PAR:IVA
|
Total Current Liabilities
€58.5m
|
CAGR 3-Years
35%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Current Liabilities
$49.4m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
20%
|
|
|
Sensorion SA
PAR:ALSEN
|
Total Current Liabilities
€14.3m
|
CAGR 3-Years
3%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Total Current Liabilities?
Total Current Liabilities
112m
EUR
Based on the financial report for Jun 30, 2025, Abivax SA's Total Current Liabilities amounts to 112m EUR.
What is Abivax SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
31%
Over the last year, the Total Current Liabilities growth was 40%. The average annual Total Current Liabilities growth rates for Abivax SA have been 49% over the past three years , 31% over the past five years .
